Frequency Therapeutics In...

NASDAQ: FREQ · Real-Time Price · USD
0.30
0.01 (4.90%)
At close: Nov 03, 2023, 8:00 PM

Company Description

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function.

Its Progenitor Cell Activation approach uses small molecules and activate progenitor cells within the body to create functional tissue.

The company's lead product candidate is FX-322, which is in Phase IIa clinical trial to treat the underlying cause of sensorineural hearing loss.

It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone.

The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, The Scripps Research Institute, and Cambridge Enterprises Limited.

Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Frequency Therapeutics Inc.
Frequency Therapeutics Inc. logo
Country United States
IPO Date Oct 3, 2019
Industry Biotechnology
Sector Healthcare
Employees 46
CEO David L. Lucchino

Advertisement

Contact Details

Address:
75 Hayden Avenue
Lexington, Massachusetts
United States
Website https://www.frequencytx.com

Stock Details

Ticker Symbol FREQ
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001703647
CUSIP Number 35803L108
ISIN Number US5009461089
Employer ID 47-2324450
SIC Code 2834

Key Executives

Name Position
Wendy S. Arnold Chief People Officer
Dr. Carl P. LeBel Ph.D. Chief Devel. Officer
Dr. Dana C. Hilt M.D. Chief Medical Officer (acting)
Dr. John L. LaMattina Ph.D. Senior Advisor & Member of PCA Regenerative Medicine Advisory Board
Dr. Lisa Geller J.D., Ph.D. Senior Vice President of Intellectual Property
Dr. Quentin McCubbin Ph.D. Chief Manufacturing Officer
Dr. William W. Chin M.D. Senior Vice President of Translational Medicine
James P. Abely Associate General Counsel & Secretary
Jason Glashow Senior Vice President of Corporation Affairs
Richard J. Mitrano Vice President of Finance & Operations
Susan Stewart J.D., L.L.M. Chief Regulatory Officer

Latest SEC Filings

Date Type Title
Apr 01, 2025 4 Filing
Apr 01, 2025 4 Filing
Apr 01, 2025 3 Filing
Mar 27, 2025 8-K Current Report
Mar 18, 2025 S-8 Filing
Mar 18, 2025 10-K Annual Report
Mar 18, 2025 8-K Current Report
Feb 14, 2025 SCHEDULE 13G/A [Amend] Filing
Feb 14, 2025 SCHEDULE 13G Filing
Feb 11, 2025 3 Filing